About

History of Nasodine

Nasodine® Nasal Spray is the product of more than 10 years of pharmaceutical R&D by Firebrick Pharma Ltd, an innovative Australian biopharmaceutical company.

Nasodine has been assessed now in six independently-controlled human clinical trials and its safety and use are supported by a growing list of peer-reviewed publications.

Firebrick Pharma owns several patents covering the unique Nasodine formulation and its use in the treatment and prevention of upper respiratory infections. The Nasodine® trademark is registered internationally by Firebrick Pharma.

2012 Founding

Firebrick Pharma was founded with the mission to develop a PVP-iodine nasal spray to kill germs in the nose.
2014-2017 Development

Development commences to create a stable nasal formulation and packaging. International patent granted on the intranasal use of PVP-iodine.
2018-2023 Human Clinical trials

Phase 1, 2 and 3 human clinical trials show that Nasodine is safe to use in the nose 4 times daily for 5 days.
2024 Nasodine international launch

Nasodine Nasal Spray becomes available for sale in selected markets, including Singapore.

Nasodine Nasal Spray is your confident choice for nasal hygiene

Power of povidone-iodine in a nasal spray
Shown in laboratory studies to kill all the germs that can cause nasal infections.
Commuting and crowds may be hotspots for germs
When people around you have symptoms, Nasodine can help protect you from other people's germs.
The right choice for healthcare professionals
Backed by 10 years of R&D, proven clinical safety, and published clinical studies.